Top Qs
Timeline
Chat
Perspective

NBOMe-escaline

Pharmaceutical compound From Wikipedia, the free encyclopedia

NBOMe-escaline
Remove ads

NBOMe-escaline, also known as escaline-NBOMe or as N-(2-methoxybenzyl)-4-ethoxy-3,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative psychedelic drug of the phenethylamine, scaline, and N-benzylphenethylamine (NBOMe) families.[1][2] It is the N-(2-methoxybenzyl) derivative of escaline.[1][2]

Quick facts Clinical data, Other names ...

The drug acts as a potent serotonin 5-HT2A receptor partial agonist, with an affinity (A2) of 0.537 nM, an activational potency (KP) of 7.08 nM, and an intrinsic activity (EmaxTooltip maximal efficacy) of 48%.[1][2] As a serotonin 5-HT2A receptor agonist in vitro, it was 7-fold more potent than NBOMe-mescaline, 50-fold more potent than escaline, and 476-fold more potent than mescaline.[1]

NBOMe-escaline was first described in the scientific literature by Heinz Pertz and colleagues by 1999.[1][2] Along with NBOMe-mescaline, it was one of the first psychedelic N-benzylphenethylamines to be discovered, slightly preceding the publication of 25-NB drugs like 25I-NBOMe by the same group of researchers.[3]

Remove ads

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads